Audrey Sternberg

Articles

HRQOL data back frontline pembrolizumab/lenvatinib in advanced RCC

June 07, 2021

The health-related quality of life data come from the phase 3 CLEAR trial. The FDA is currently reviewing efficacy data from this trial supporting an application for pembrolizumab plus lenvatinib in frontline renal cell carcinoma.